Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2013 | 02:40pm CET

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
12/04 CELGENE : Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 St..
12/04 CELGENE CORPORATION : Dana-Farber Cancer Institute and University of Arkansas fo..
12/01 CELGENE : Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at A..
12/01 HERE’S WHAT’S SO IMPORTA : BLUE) Data
11/30 CELGENE : LLS Receives Prestigious Innovation Impact Award to 'Reach the Unreach..
11/22 CELGENE : PharmAkea Extends Collaboration with Celgene Corporation
11/22 CELGENE : Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at A..
11/21 WHAT’S NEXT AT GLOBEIMMUNE INC : Gbim)?
11/21 CELGENE CORPORATION : to Webcast an Analyst and Investor Event from the American..
11/19 CELGENE : Triphase Accelerator Corporation Announces Full Enrollment Results of ..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/04 Juno's JCAR014 shows positive results in early stage study in treatment-resis..
12/02 Celgene to buy Acetylon Pharmaceuticals
12/02 STOCK EXCHANGE : Model Picks Teach Us To Manage Risk
12/01 ALLERGAN : Low Enough To Like, Or Valeant-Lite?
12/01 Triple Meeting - Bluebird Upstages Its Ash Rivals
Advertisement
Financials ($)
Sales 2016 11 290 M
EBIT 2016 6 002 M
Net income 2016 2 540 M
Debt 2016 5 032 M
Yield 2016 -
P/E ratio 2016 37,10
P/E ratio 2017 21,58
EV / Sales 2016 8,52x
EV / Sales 2017 7,24x
Capitalization 91 187 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 139 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-1.78%91 187
AMGEN, INC.-11.29%107 132
GILEAD SCIENCES, INC.-28.02%95 410
REGENERON PHARMACEUTIC..-31.34%39 310
ACTELION LTD40.40%21 739
VERTEX PHARMACEUTICALS..-38.15%18 727
More Results